Chondroitin sulfate expression predicts poor outcome in breast cancer

International Journal of Oncology

Volumn 39, Issue 6, 2011, Pages 1421-1428

  Svensson, Katrin J ^a   Christianson, Helena C ^a   Paulina, Kucharzewska ^a   Victor, Fagerstrom̈ ^a   Lars, Lundstedt ^a   Signe, Borgquist ^a   Karin, Jirstrom̈ ^a   Belting, Mattias ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Breast cancer; Chondroitin sulfate; Proteoglycan

Indexed keywords

ANTINEOPLASTIC AGENT; CHONDROITIN SULFATE;

ADVERSE OUTCOME; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENT CANCER; STROMA CELL;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CELL LINE, TUMOR; CHONDROITIN SULFATES; DISEASE PROGRESSION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; PHENOTYPE; PROGNOSIS;

EID: 80054804895     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1164     Document Type: Article

References (48)

1. Heldin CH, Rubin K, Pietras K and Ostman A: High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 10: 806-813, 2004. (Pubitemid 39331152)
2. Radisky DC, Stallings-Mann M, Hirai Y and Bissell MJ: Single proteins might have dual but related functions in intracellular and extracellular microenvironments. Nat Rev Mol Cell Biol 3: 228-234, 2009.
3. Belting M: Heparan sulfate proteoglycan as a plasma membrane carrier. Trends Biochem Sci 28: 145-151, 2003.
4. Fuster MM and Esko JD: The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer 5: 526-542, 2005. (Pubitemid 40942829)
5. Jakobsson L, Kreuger J, Holmborn K, et al.: Heparan sulfate in trans potentiates VEGFR-mediated angiogenesis. Dev Cell 10: 625-634, 2006.
6. Malavaki C, Mizumoto S, Karamanos N and Sugahara K: Recent advances in the structural study of functional chondroitin sulfate and dermatan sulfate in health and disease. Connect Tissue Res 49: 133-139, 2008.
7. Wegrowski Y and Maquart FX: Chondroitin sulfate proteoglycans in tumor progression. Adv Pharmacol 53: 297-321, 2006.
8. Li F, Ten Dam GB, Murugan S, et al.: Involvement of highly sulfated chondroitin sulfate in the metastasis of the Lewis lung carcinoma cells. J Biol Chem 283: 34294-34304, 2008.
9. Sugahara KN, Hirata T, Tanaka T, et al.: Chondroitin sulfate fragments enhance CD44 cleavage and CD44-dependent motility in tumor cells. Cancer Res 68: 7191-7199, 2008.
10. Cortes M, Baria AT and Schwartz NB: Sulfation of chondroitin sulfate proteoglycans is necessary for proper Indian hedgehog signaling in the developing growth plate. Development 136: 1697-1706, 2009.
11. Ozzello L, Lasfargues EY and Murray MR: Growth-promoting activity of acid mucopolysaccharides on a strain of human mammary carcinoma cells. Cancer Res 20: 600-604, 1960.
12. Chandrasekaran EV and Davidson EA: Glycosaminoglycans of normal and malignant cultured human mammary cells. Cancer Res 39: 870-880, 1979. (Pubitemid 9143279)
13. Gowda DC, Bhavanandan VP and Davidson EA: Isolation and characterization of proteoglycans secreted by normal and malignant human mammary epithelial cells. J Biol Chem 261: 4926-4934, 1986. (Pubitemid 17204282)
14. Alini M and Losa GA: Partial characterization of proteoglycans isolated from neoplastic and nonneoplastic human breast tissues. Cancer Res 51: 1443-1447, 1991.
15. Suwiwat S, Ricciardelli C, Tammi R, et al.: Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer. Clin Cancer Res 10: 2491-2498, 2004. (Pubitemid 38445711)
16. Welch JE, Bengtson P, Svensson K, et al.: Single chain fragment anti-heparan sulfate antibody targets the polyamine transport system and attenuates polyamine-dependent cell proliferation. Int J Oncol 32: 749-756, 2008. (Pubitemid 351780585)
17. Kucharzewska P, Welch JE, Svensson KJ and Belting M: Ornithine decarboxylase and extracellular polyamines regulate microvascular sprouting and actin cytoskeleton dynamics in endothelial cells. Exp Cell Res 16: 2683-91, 2010.
18. Brennan DJ, Rexhepaj E, O'Brien SL, et al.: Altered cytoplasmic-to- nuclear ratio of survivin is a prognostic indicator in breast cancer. Clin Cancer Res 14: 2681-2689, 2008.
19. Borgquist S, Jögi A, Pontén F, Rydén L, Brennan DJ and Jirström K: Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer. Breast Cancer Res 10: R79, 2008.
20. O'Brien SL, Fagan A, Fox EJ, et al.: CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer. Int J Cancer 120: 1434-1443, 2007. (Pubitemid 46355377)
21. Paulsson J, Sjoblom T, Micke P, et al.: Prognostic significance of stromal platelet-derived growth factor beta receptor expression in human breast cancer. Am J Pathol 175: 334-341, 2009.
22. Kononen J, Bubendorf L, Kallionimeni A, et al.: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4: 844-847, 1998. (Pubitemid 28331029)
23. Borgquist S, Holm C, Stendahl M, Anagnostaki L, Landberg G and Jirstrom K: Oestrogen receptors alpha and beta show different associations to clinicopathological parameters and their coexpression might predict a better response to endocrine treatment in breast cancer. J Clin Pathol 61: 197-203, 2008.
24. Ito Y, Hikino M, Yajima Y, et al.: Structural characterization of the epitopes of the monoclonal antibodies 473HD, CS-56, and MO-225 specific for chondroitin sulfate D-type using the oligosaccharide library. Glycobiology 15: 593-603, 2005. (Pubitemid 41214372)
25. Adany R, Heimer R, Caterson B, Sorrell JM and Iozzo RV: Altered expression of chondroitin sulfate proteoglycan in the stroma of colon cancer. J Biol Chem 265: 1389-1396, 1990.
26. Cohen IR, Murdoch AD, Naso MF, Marchetti D, Berd D and Iozzo RV: Abnormal expression of perlecan proteoglycan in metastatic melanomas. Cancer Res 54: 5771-5774, 1994. (Pubitemid 24375201)
27. Santra M, Skorski T, Calabretta TB, Lattime EC and Iozzo RV: De novo decorin gene expression suppresses the malignant phenotype in human colon cancer cells. Proc Natl Acad Sci USA 92: 7016-7020, 1995.
28. Ricciardelli C, Mayne K, Sykes PJ, et al.: Elevated stromal chondroitin sulfate glycosaminoglycan predicts progression in early-stage prostate cancer. Clin Cancer Res 3: 983-992, 1997. (Pubitemid 27252948)
29. Ricciardelli C, Mayne K, Sykes PJ, et al.: Elevated levels of versican but not decorin predict disease progression in early-stage prostate cancer. Clin Cancer Res 4: 963-971, 1998. (Pubitemid 28183398)
30. Ricciardelli C, Brooks JH, Suwiwat S, et al.: Regulation of stromal versican expression by breast cancer cells and importance to relapse-free survival in patients with node-negative primary breast cancer. Clin Cancer Res 8: 1054-1060, 2002. (Pubitemid 35177355)
31. Troup S, Njue C, Kliewer EV, et al.: Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer. Clin Cancer Res 9: 207-214, 2003. (Pubitemid 36109735)
32. Loussouarn D, Campion L, Sagan C, et al.: Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas. Br J Cancer 98: 1993-1998, 2008. (Pubitemid 351821565)
33. Goldoni S and Iozzo RV: Tumor microenvironment: Modulation by decorin and related molecules harboring leucine-rich tandem motifs. Int J Cancer 123: 2473-2479, 2008.
34. Ricciardelli C, Sakko AJ, Ween MP, Russell DL and Horsfall DJ: The biological role and regulation of versican levels in cancer. Cancer Metastasis Rev 28: 233-245, 2009.
35. Muraoka RS, Dumont N, Ritter CA, et al.: Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 109: 1551-1559, 2002. (Pubitemid 34663517)
36. Vincent T, Neve EP, Johnson JR, et al.: A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-beta mediated epithelial-mesenchymal transition. Nat Cell Biol 11: 943-950, 2009.
37. Desruisseau S, Palmari J, Giusti C, Romain S, Martin PM and Berthois Y: Determination of TGFbeta1 protein level in human primary breast cancers and its relationship with survival. Br J Cancer 94: 239-246, 2006. (Pubitemid 43151542)
38. Rapraeger A: Transforming growth factor (type beta) promotes the addition of chondroitin sulfate chains to the cell surface proteoglycan (syndecan) of mouse mammary epithelia. J Cell Biol 109: 2509-2518, 1989.
39. Heredia A, Villena J, Romarís M, Molist A and Bassols A: Transforming growth factor beta 1 increases the synthesis and shedding of the melanoma-specific proteoglycan in human melanoma cells. Arch Biochem Biophys 333: 198-206, 1996. (Pubitemid 26276991)
40. Romarís M, Bassols A and David G: Effect of transforming growth factor-beta 1 and basic fibroblast growth factor on the expression of cell surface proteoglycans in human lung fibroblasts. Enhanced glycanation and fibronectin-binding of CD44 proteoglycan, and down-regulation of glypican. Biochem J 310: 73-81, 1995.
41. Prante C, Milting H, Kassner A, et al.: Transforming growth factor beta1-regulated xylosyltransferase I activity in human cardiac fibroblasts and its impact for myocardial remodeling. J Biol Chem 282: 26441-26449, 2007. (Pubitemid 47443782)
42. Tiedemann K, Olander B, Eklund E, et al.: Regulation of the chondroitin/dermatan fine structure by transforming growth factor-beta1 through effects on polymer-modifying enzymes. Glycobiology 15: 1277-1285, 2005. (Pubitemid 41724332)
43. Willis CM, Wrana JL and Klüppel M: Identification and characterization of TGFbeta-dependent and -independent cis-regulatory modules in the C4ST-1/CHST11 locus. Genet Mol Res 8: 1331-1343, 2009.
44. Yamada S and Sugahara K: Potential therapeutic application of chondroitin sulfate/dermatan sulfate. Curr Drug Discov Technol 5: 289-301, 2008.
45. Pumphrey CY, Theus AM, Li S, Parrish RS and Sanderson RD: Neoglycans, carbodiimide-modified glycosaminoglycans: a new class of anticancer agents that inhibit cancer cell proliferation and induce apoptosis. Cancer Res 62: 3722-3728, 2002. (Pubitemid 34728853)
46. Borsig L, Wang L, Cavalcante MC, et al.: Selectin blocking activity of a fucosylated chondroitin sulfate glycosaminoglycan from sea cucumber. Effect on tumor metastasis and neutrophil recruitment. J Biol Chem 282: 14984-14991, 2007. (Pubitemid 47093354)
47. Altinbas M, Coskun HS, Er O, et al.: A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2: 1266-1271, 2004. (Pubitemid 40186120)
48. Klerk C, Smorenburg SM, Otten HM, et al.: The effect of LMWH on survival in patients with advanced malignancy. J Clin Oncol 23: 2130-2135, 2005. (Pubitemid 46218704)